Residency · Residency · Internal Medicine

Approach to Abnormal Liver Tests in the Outpatient Setting

Start here

Alright, settle in. I know it’s been a long day, and your pager is probably buzzing about that admit from the ER. But before you get lost in the EMR, let’s talk about that routine follow-up you saw this morning – the one with those slightly wonky liver tests. Remember Mrs. Gable, seventy-two, with a new statin and her annual labs showing an ALT of 80? Your first thought might be, “Oh no, liver failure!” But let’s pump the brakes. Most often, these aren't flashing red lights, just amber ones. We’re not looking for liver function tests, because alanine aminotransferase (ALT) and aspartate aminotransferase (AST) tell us about injury, not necessarily how well the liver is actually working. Her albumin and international normalized ratio (INR) were normal, right? Good. That means her liver is still doing its heavy lifting, synthesizing proteins and clotting factors just fine.

So, what’s going on with that ALT? You’ve got a few big buckets to think about. Is it a hepatocellular problem, meaning liver cell damage, like we see with ALT and AST? Or is it cholestatic, pointing to bile flow issues, typically signaled by elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT)? For Mrs. Gable, with her ALT predominantly elevated, we're thinking hepatocellular. The most common culprit you're going to see in clinic these days is metabolic dysfunction-associated steatotic liver disease (MASLD), especially if she has any metabolic risk factors. Then there’s alcohol – always ask, gently. And don't forget her new statin; drug-induced liver injury (DILI) is always on the differential, especially with new medications. Viral hepatitis (B and C), iron overload, and even autoimmune issues are less common but important to rule out.

The key is to not get overwhelmed. Instead of ordering a shotgun panel, think systematically. We start with the most common things, rule those out, and then move to the less common. For Mrs. Gable, we'd confirm the pattern, then check her hepatitis serologies, iron studies, maybe a non-invasive fibrosis score like FIB-4 if you suspect MASLD, and definitely look at that statin. If you keep this pattern-based approach in mind, you’ll navigate these abnormal labs like a pro, and Mrs. Gable (and her liver) will thank you.

Introduction

Abnormal liver tests are among the most common laboratory findings encountered in outpatient internal medicine, affecting up to 10% of the US population. A systematic approach to interpretation, categorization of the pattern of injury, and targeted workup can efficiently narrow the differential and guide management. The terminology "liver tests" is preferred over "liver function tests" since aminotransferases reflect hepatocellular injury, not synthetic function.

Understanding the Tests

Markers of Hepatocellular Injury

• ALT (alanine aminotransferase): most specific marker for hepatocyte injury; found primarily in hepatocytes
• AST (aspartate aminotransferase): present in liver, cardiac muscle, skeletal muscle, kidneys, and red blood cells; less liver-specific
• AST:ALT ratio > 2: suggests alcohol-related liver disease (De Ritis ratio); also seen in cirrhosis of any etiology
• Mild elevations (< 5x ULN) are the most common pattern encountered in practice

Markers of Cholestasis

• Alkaline phosphatase (ALP): present in liver, bone, intestine, placenta; confirm hepatic origin with GGT or 5'-nucleotidase
• GGT (gamma-glutamyl transferase): sensitive but non-specific; elevated by alcohol, medications, obesity
• Direct (conjugated) bilirubin: elevation indicates impaired biliary excretion

Markers of Synthetic Function

• Albumin: half-life of 21 days; reflects chronic synthetic capacity (also affected by inflammation, nephrotic syndrome, malnutrition)
• Prothrombin time / INR: reflects hepatic synthesis of clotting factors (II, V, VII, X); earliest marker of acute synthetic failure
• Platelet count: thrombocytopenia may suggest portal hypertension and advanced fibrosis/cirrhosis

Pattern-Based Approach

Hepatocellular Pattern (Elevated ALT/AST, Normal or Mildly Elevated ALP)

• Calculate the R-value: (ALT / ALT ULN) divided by (ALP / ALP ULN)
• R > 5: hepatocellular; R < 2: cholestatic; R 2-5: mixed

Initial Workup for Hepatocellular Injury

• Metabolic dysfunction-associated steatotic liver disease (MASLD): most common cause; assess BMI, metabolic syndrome, obtain hepatic steatosis index or ultrasound
• Alcohol-associated liver disease: detailed alcohol history; AST:ALT > 2, elevated GGT
• Viral hepatitis: hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), hepatitis B core antibody (anti-HBc), hepatitis C antibody (anti-HCV) with reflex RNA
• Medications/supplements: review all prescription drugs, OTC medications, and herbal supplements (acetaminophen, statins, NSAIDs, antibiotics, supplements)
• Hemochromatosis: transferrin saturation (> 45% warrants HFE gene testing), ferritin
• Autoimmune hepatitis: ANA, ASMA, IgG levels; consider anti-LKM-1 in younger patients
• Wilson disease: ceruloplasmin (screen in patients < 40 years with unexplained liver disease)
• Alpha-1 antitrypsin deficiency: alpha-1 antitrypsin level and phenotyping
• Celiac disease: tissue transglutaminase IgA (often overlooked cause)
• Thyroid disease: TSH

Cholestatic Pattern (Elevated ALP with or without Elevated Bilirubin)

• Confirm hepatic origin of ALP with GGT
• Imaging first: right upper quadrant ultrasound to assess for biliary dilation
• Dilated ducts: extrahepatic obstruction (choledocholithiasis, pancreatic mass, cholangiocarcinoma) -- proceed to MRCP or ERCP
• Non-dilated ducts: intrahepatic cholestasis

Intrahepatic Cholestasis Workup

• Primary biliary cholangitis (PBC): anti-mitochondrial antibody (AMA), IgM elevation; predominantly affects middle-aged women
• Primary sclerosing cholangitis (PSC): MRCP showing multifocal biliary strictures; associated with IBD (especially ulcerative colitis); pANCA may be positive
• Drug-induced cholestasis: amoxicillin-clavulanate, anabolic steroids, oral contraceptives
• Infiltrative disease: sarcoidosis, lymphoma, amyloidosis

Isolated Hyperbilirubinemia

• Unconjugated (indirect): Gilbert syndrome (most common, benign, affects 5-10% of population), hemolysis, ineffective erythropoiesis
• Conjugated (direct): Dubin-Johnson syndrome, Rotor syndrome, hepatocellular or cholestatic disease

MASLD and MASH: The Epidemic

• MASLD (formerly NAFLD): hepatic steatosis with at least one cardiometabolic risk factor
• MASH (formerly NASH): steatosis with inflammation and hepatocyte ballooning +/- fibrosis
• Prevalence: 25-30% of adults; leading cause of chronic liver disease globally
• FIB-4 index: non-invasive fibrosis score using age, AST, ALT, and platelet count
• FIB-4 < 1.3: low risk (negative predictive value > 90%)
• FIB-4 >= 1.3: consider transient elastography (FibroScan) or enhanced liver fibrosis (ELF) test
• Resmetirom (Rezdiffra): first FDA-approved therapy for MASH with moderate-to-advanced fibrosis (thyroid hormone receptor-beta agonist)
• Weight loss of >= 7-10% can achieve histologic improvement; GLP-1 RAs show promise

When to Refer to Hepatology

• ALT/AST > 10x ULN (acute liver injury) or signs of acute liver failure
• Suspected autoimmune hepatitis, PBC, PSC, or Wilson disease
• Advanced fibrosis on non-invasive testing (FIB-4 >= 2.67 or liver stiffness >= 9.7 kPa)
• Need for liver biopsy
• Cirrhosis and its complications
• Unexplained liver test abnormalities persisting beyond 6 months of workup

Drug-Induced Liver Injury (DILI)

• Consider DILI in any patient with new liver test abnormalities
• Intrinsic DILI: dose-dependent, predictable (e.g., acetaminophen)
• Idiosyncratic DILI: unpredictable, not dose-dependent; latency weeks to months
• LiverTox database (NIH): essential resource for evaluating suspected DILI
• Common culprits: antibiotics (amoxicillin-clavulanate #1), NSAIDs, antiepileptics, statins, herbal/dietary supplements (especially green tea extract, turmeric)

Key Clinical Pearls

• MASLD is now the most common cause of mildly elevated aminotransferases; use FIB-4 as the first-line non-invasive fibrosis assessment
• An AST:ALT ratio > 2 strongly suggests alcohol-related liver disease but can also be seen in cirrhosis of any cause
• Always check hepatitis B and C serologies in any patient with unexplained transaminase elevation; both are treatable
• Statins are safe in patients with chronic liver disease and MASLD; they are only contraindicated in acute liver injury or decompensated cirrhosis

References

1. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35.
2. Rinella ME, Lazarus JV, Ratziu V, et al. A Multi-Society Delphi Consensus Statement on New Fatty Liver Disease Nomenclature (MASLD). Hepatology. 2023;78(6):1966-1986.
3. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509.
4. Chalasani N, Bonkovsky HL, Fontana RJ, et al. Features and Outcomes of 899 Patients with Drug-Induced Liver Injury (DILIN). Gastroenterology. 2015;148(7):1340-1352.

For the intern

At 3am, if consulted for abnormal liver tests, first establish if this is acute liver injury (ALT/AST > 10x upper limit of normal [ULN]) with coagulopathy or encephalopathy—these patients need urgent hepatology consultation and transfer to a center with transplant capability. Check acetaminophen level immediately if there's any suspicion. For incidental mild elevations discovered during hospitalization, these can wait until morning for systematic workup. Document medication and supplement history carefully, review imaging if already done, and place orders for basic serologies (hepatitis B and C, metabolic panel). Most abnormal liver tests in the outpatient setting represent chronic processes that don't require middle-of-the-night interventions.

Common pitfalls

• Failing to confirm hepatic origin of elevated alkaline phosphatase (ALP): Always order gamma-glutamyl transferase (GGT) to distinguish hepatobiliary from bone, intestinal, or pregnancy-related ALP elevation. Ordering an ALP fractionation or 5'-nucleotidase works too, but GGT is faster and cheaper.

• Ordering right upper quadrant ultrasound for hepatocellular patterns: Ultrasound is essential for cholestatic patterns to evaluate for ductal dilation and obstruction, but adds little value early in hepatocellular injury workup. Start with serologies and risk factor assessment.

• Missing alcohol-associated liver disease: Many patients underreport consumption. An aspartate aminotransferase (AST):alanine aminotransferase (ALT) ratio > 2 with both values < 300 IU/L should prompt direct, non-judgmental questioning about drinking patterns.

• Stopping statins unnecessarily: Mild transaminase elevation (< 3x ULN) is not a contraindication to statin therapy. Statins reduce cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) and should be continued unless acute liver injury develops.

Make it stick

Imagine Mrs. Rodriguez, a 62-year-old with type 2 diabetes and obesity, presenting with fatigue. Routine labs show an AST of 78 U/L and ALT of 105 U/L (both <2x ULN). Your first thought isn't a rare autoimmune disease or exotic infection. Instead, you immediately consider metabolic dysfunction-associated steatotic liver disease (MASLD). A quick FIB-4 calculation (age, AST, ALT, platelets) estimates her risk of advanced fibrosis. An abdominal ultrasound confirms steatosis. This common scenario highlights how a systematic, pattern-based approach, prioritizing MASLD, streamlines the workup for the vast majority of abnormal liver tests in primary care, focusing on modifiable risk factors.

If you remember one thing

The vast majority of abnormal liver tests in the outpatient setting are due to MASLD, so always consider this first and use non-invasive scoring systems like FIB-4 to assess for fibrosis. Always confirm the hepatic origin of an isolated alkaline phosphatase elevation with a GGT.

Read this lecture as Markdown